XENON PHARMACEUTICALS INC. (XENE) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $2.43B; Additional Paid in Capital, Common StockUSD $276.85M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-2.66M; Retained Earnings (Accumulated Deficit)USD $-1.46B.
- 2026-03-31: Common Stock, Value, IssuedUSD $2.42B; Additional Paid in Capital, Common StockUSD $264.88M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.21M; Retained Earnings (Accumulated Deficit)USD $-1.35B.
- 2025-12-31: Common Stock, Value, IssuedUSD $1.60B; Additional Paid in Capital, Common StockUSD $228.23M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $335.00K; Retained Earnings (Accumulated Deficit)USD $-1.25B.
- 2025-09-30: Common Stock, Value, IssuedUSD $1.48B; Additional Paid in Capital, Common StockUSD $223.78M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $477.00K; Retained Earnings (Accumulated Deficit)USD $-1.14B.
XENON PHARMACEUTICALS INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD | Additional Paid in Capital USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Adjustments to Additional Paid in Capital, Other USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.43B | $276.85M | $-2.66M | $-1.46B | $1.24B | 3 month · $16.73M | (m) | (m) | (m) | (m) |
| 2026-03-31 | $2.42B | $264.88M | $-1.21M | $-1.35B | $1.34B | 3 month · $16.89M | (m) | (m) | (m) | (m) |
| 2025-12-31 | $1.60B | $228.23M | $335.00K | $-1.25B | $581.76M | 12 month · $53.71M | (m) | (m) | (m) | (m) |
| 2025-09-30 | $1.48B | $223.78M | $477.00K | $-1.14B | $559.51M | 3 month · $13.71M | (m) | (m) | (m) | (m) |
| 2025-06-30 | $1.47B | $213.89M | $113.00K | $-1.05B | $633.98M | 3 month · $13.71M | (m) | (m) | (m) | (m) |
| 2025-03-31 | $1.46B | $208.46M | $-836.00K | $-964.52M | $703.96M | 3 month · $12.17M | (m) | (m) | (m) | (m) |
| 2024-12-31 | $1.46B | $199.15M | $-1.61M | $-899.47M | $754.90M | 12 month · $50.72M | (m) | (m) | (m) | (m) |
| 2024-09-30 | $1.44B | $188.44M | $1.34M | $-833.78M | $797.81M | 3 month · $13.00M | (m) | (m) | (m) | (m) |
| 2024-06-30 | $1.44B | $176.80M | $-2.21M | $-771.00M | $844.05M | 3 month · $14.72M | (m) | (m) | (m) | (m) |
| 2024-03-31 | $1.44B | $163.58M | $-1.77M | $-713.07M | $887.70M | 3 month · $9.40M | (m) | (m) | (m) | (m) |
| 2023-12-31 | $1.44B | $156.76M | $-77.00K | $-665.14M | $927.92M | 12 month · $32.37M | (m) | (m) | (m) | (m) |
| 2023-09-30 | $1.12B | $137.97M | $-2.95M | $-620.40M | $636.59M | 3 month · $8.74M | (m) | (m) | (m) | (m) |
| 2023-06-30 | $1.08B | $138.68M | $-3.30M | $-571.93M | $646.46M | 3 month · $8.45M | (m) | (m) | (m) | (m) |
| 2023-03-31 | $1.07B | $140.09M | $-1.82M | $-524.47M | $686.94M | 3 month · $5.99M | (m) | (m) | (m) | (m) |
| 2022-12-31 | $1.07B | $142.11M | $-3.00M | $-482.75M | $721.50M | 12 month · $20.38M | (m) | (m) | (m) | (m) |
| 2022-09-30 | $1.06B | $136.73M | $-2.96M | $-445.35M | $753.12M | 3 month · $5.74M | $0.00 | (m) | (m) | (m) |
| 2022-06-30 | $1.06B | $133.29M | $-990.00K | $-408.20M | $785.79M | 3 month · $5.21M | $0.00 | (m) | (m) | (m) |
| 2022-03-31 | $800.31M | $119.58M | $-990.00K | $-377.04M | $541.85M | 3 month · $3.61M | $0.00 | (m) | (m) | (m) |
| 2021-12-31 | $783.17M | $117.50M | $-990.00K | $-357.37M | $550.03M | 12 month · $10.02M | $7.73M | (m) | (m) | (m) |
| 2021-09-30 | $504.39M | $69.62M | $-990.00K | $-331.81M | $248.94M | 3 month · $2.64M | $7.73M | (m) | (m) | (m) |
| 2021-06-30 | $499.35M | $67.25M | $-990.00K | $-316.37M | $256.98M | 3 month · $2.70M | $7.73M | (m) | (m) | (m) |
| 2021-03-31 | $498.33M | $65.46M | $-990.00K | $-294.26M | $276.28M | 3 month · $1.97M | $7.73M | (m) | (m) | (m) |
| 2020-12-31 | $397.75M | $45.36M | $-990.00K | $-278.49M | $171.35M | 12 month · $5.68M | $7.73M | (m) | (m) | (m) |
| 2020-09-30 | $397.65M | $43.80M | $-990.00K | $-266.17M | $182.02M | 3 month · $1.58M | $7.73M | (m) | (m) | (m) |
| 2020-06-30 | $397.65M | $42.22M | $-990.00K | $-257.31M | $189.30M | 3 month · $1.47M | $7.73M | (m) | (m) | (m) |
| 2020-03-31 | $397.31M | $41.07M | $-990.00K | $-257.14M | $187.98M | 3 month · $1.01M | $7.73M | (m) | (m) | (m) |
| 2019-12-31 | $294.24M | $40.65M | $-990.00K | $-249.66M | $91.98M | 12 month · $2.93M | $7.73M | (m) | (m) | (m) |
| 2019-09-30 | $266.43M | $39.68M | $-990.00K | $-238.28M | $74.56M | 3 month · $630.00K | $7.73M | (m) | (m) | (m) |
| 2019-06-30 | $266.06M | $39.39M | $-990.00K | $-229.41M | $82.79M | 3 month · $470.00K | $7.73M | (m) | (m) | (m) |
| 2019-03-31 | $266.04M | $38.93M | $-990.00K | $-219.40M | $92.31M | 3 month · $476.00K | $7.73M | (m) | (m) | (m) |
| 2018-12-31 | $265.92M | $38.52M | $-990.00K | $-207.88M | $103.30M | 12 month · $2.65M | $7.73M | (m) | 12 month · $538.00K | (m) |
| 2018-09-30 | $261.65M | $37.89M | $-990.00K | $-199.33M | $111.16M | 3 month · $662.00K 9 month · $1.99M | $11.93M | (m) | 3 month · $291.00K 9 month · $538.00K | (m) |
| 2018-06-30 | $177.01M | $37.72M | $-990.00K | $-184.94M | $50.62M | 3 month · $657.00K 6 month · $1.33M | $21.82M | (m) | 3 month · $247.00K 6 month · $247.00K | (m) |
| 2018-03-31 | $147.89M | $36.92M | $-990.00K | $-177.14M | $28.50M | 3 month · $670.00K | $21.82M | (m) | (m) | (m) |
| 2017-12-31 | $173.84M | $36.47M | $-990.00K | $-173.39M | $35.93M | 12 month · $2.46M | (m) | (m) | 12 month · $100.00K | (m) |
| 2017-09-30 | $173.84M | $35.77M | $-990.00K | $-165.32M | $43.30M | 9 month · $1.86M | (m) | (m) | (m) | (m) |
| 2017-06-30 | $173.84M | $35.18M | $-990.00K | $-157.58M | $50.45M | 6 month · $1.27M | (m) | (m) | (m) | (m) |
| 2017-03-31 | $173.83M | $34.56M | $-990.00K | $-150.20M | $57.20M | 3 month · $637.00K | (m) | (m) | (m) | (m) |
| 2016-12-31 | $173.25M | $34.33M | $-990.00K | $-142.68M | $63.90M | 12 month · $2.19M | (m) | (m) | (m) | (m) |
| 2016-09-30 | $172.89M | $34.12M | $-990.00K | $-136.70M | $69.31M | 9 month · $1.64M | (m) | (m) | (m) | (m) |
| 2016-06-30 | $148.87M | $33.75M | $-990.00K | $-128.97M | $52.66M | 6 month · $1.11M | (m) | (m) | (m) | (m) |
| 2016-03-31 | $148.73M | $33.38M | $-990.00K | $-122.96M | $58.16M | 3 month · $634.00K | (m) | (m) | (m) | (m) |
| 2015-12-31 | $148.63M | $33.08M | $-990.00K | $-119.69M | $61.03M | 12 month · $2.08M | (m) | (m) | (m) | (m) |
| 2015-09-30 | $148.36M | $32.84M | $-990.00K | $-115.75M | $64.46M | 9 month · $1.60M | (m) | (m) | (m) | (m) |
| 2015-06-30 | $147.82M | $29.31M | $-990.00K | $-111.80M | $64.35M | 6 month · $661.00K | (m) | (m) | (m) | (m) |
| 2015-03-31 | $147.51M | $29.08M | $-990.00K | $-112.93M | $62.67M | 3 month · $239.00K | (m) | (m) | (m) | (m) |
| 2014-12-31 | $147.16M | $30.35M | $-990.00K | $-103.73M | $72.78M | 12 month · $760.00K | (m) | $30.35M | (m) | (m) |
| 2014-09-30 | $6.20M | (m) | $1.01M | $-104.96M | $-67.51M | 9 month · $561.00K | $102.49M | $30.24M | (m) | (m) |
| 2013-12-31 | $6.15M | (m) | $2.51M | $-116.75M | $-78.37M | 12 month · $575.00K | $102.49M | $29.72M | (m) | 12 month · $73.00K |
| 2012-12-31 | (m) | (m) | (m) | (m) | $-89.86M | 12 month · $406.00K | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | $-86.32M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |